Senator Investment Group LP decreased its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 31.3% during the 2nd quarter, HoldingsChannel reports. The fund owned 1,030,000 shares of the specialty pharmaceutical company’s stock after selling 468,295 shares during the quarter. Jazz Pharmaceuticals accounts for 1.8% of Senator Investment Group LP’s investment portfolio, making the stock its 24th biggest holding. Senator Investment Group LP’s holdings in Jazz Pharmaceuticals were worth $177,469,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Summit Trail Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 8,591.5% during the 1st quarter. Summit Trail Advisors LLC now owns 102,125 shares of the specialty pharmaceutical company’s stock worth $102,000 after buying an additional 100,950 shares in the last quarter. Financial Gravity Wealth Inc. bought a new position in shares of Jazz Pharmaceuticals during the 1st quarter worth approximately $192,000. Tiverton Asset Management LLC bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth approximately $198,000. Moloney Securities Asset Management LLC bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth approximately $204,000. Finally, FDx Advisors Inc. bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth approximately $244,000. 92.50% of the stock is currently owned by institutional investors and hedge funds.

In other news, CFO Matthew P. Young sold 700 shares of the firm’s stock in a transaction that occurred on Monday, July 16th. The shares were sold at an average price of $176.06, for a total transaction of $123,242.00. Following the completion of the sale, the chief financial officer now owns 34,868 shares in the company, valued at approximately $6,138,860.08. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Bruce C. Cozadd sold 1,600 shares of the firm’s stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $170.81, for a total transaction of $273,296.00. Following the sale, the chief executive officer now owns 284,115 shares of the company’s stock, valued at approximately $48,529,683.15. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 33,078 shares of company stock valued at $5,741,163. 3.90% of the stock is currently owned by company insiders.

Several research firms have commented on JAZZ. BidaskClub cut shares of Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 28th. Stifel Nicolaus lifted their target price on shares of Jazz Pharmaceuticals from $180.00 to $205.00 and gave the stock a “buy” rating in a research report on Wednesday, August 8th. B. Riley lifted their target price on shares of Jazz Pharmaceuticals from $211.00 to $219.00 and gave the stock a “buy” rating in a research report on Tuesday, June 26th. Wells Fargo & Co reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Monday, July 2nd. Finally, BMO Capital Markets lifted their target price on shares of Jazz Pharmaceuticals from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 8th. Two analysts have rated the stock with a sell rating, five have given a hold rating and seventeen have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $190.71.

Shares of JAZZ stock opened at $163.07 on Monday. The company has a quick ratio of 3.62, a current ratio of 3.76 and a debt-to-equity ratio of 0.54. Jazz Pharmaceuticals PLC has a 12-month low of $128.58 and a 12-month high of $184.00. The company has a market cap of $10.02 billion, a PE ratio of 17.06, a P/E/G ratio of 0.90 and a beta of 1.04.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $3.49 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.23 by $0.26. Jazz Pharmaceuticals had a net margin of 24.20% and a return on equity of 25.47%. The company had revenue of $500.48 million during the quarter, compared to analyst estimates of $469.85 million. equities analysts forecast that Jazz Pharmaceuticals PLC will post 11.7 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Recommended Story: Penny Stocks, What You Need To Know

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.